Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

Rhea-AI Summary

Scopus BioPharma (Nasdaq: SCPS) announced the presentation of key scientific data at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 8-12, 2022, in Boston, Massachusetts. The company, dedicated to developing transformational therapeutics for unmet medical needs, operates through its immuno-oncology subsidiary, Duet BioTherapeutics. Launched in September 2021, Duet focuses on innovative immunotherapy assets, including three CpG-STAT3 inhibitors. The press release also includes a disclaimer regarding forward-looking statements and associated risks.

Positive

• Presentation of key scientific data at SITC highlights company's research efforts and potential in immunotherapy.
• Duet BioTherapeutics consolidates immunotherapy assets, showcasing diverse CpG-STAT3 inhibitors.

Negative

• Forward-looking statements indicate uncertainties that might affect future performance.

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37^th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer (“SITC”).

SITC is being held from November 8-12, 2022 at the Boston Convention and Exhibition Center in Boston, Massachusetts.

About Scopus BioPharma

Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. Duet BioTherapeutics, a majority-owned subsidiary of Scopus, was launched in September 2021 by Scopus BioPharma to consolidate its immunotherapy assets. These assets include three distinctive complementary CpG-STAT3 inhibitors: RNA silencing – CpG-STAT3siRNA – (“DUET-01”); Antisense – CpG-STAT3ASO – (“DUET-02”); and DNA-binding inhibitor – CpG-STAT3decoy – (“DUET-03”). The Company is also developing additional drug candidates and seeking to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions.

Forward-Looking Statements

This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the Company’s Form 10-K for the fiscal year ended December 31, 2020, as amended, filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Further, there can be no assurance that the Company will identify and/or consummate any transaction relating to any additional technologies.

Contacts

Rodd Leeds/David Waldman
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: SCPS@crescendo-ir.com

Hugh Burns/Delia Cannan/Nicholas Leasure
Reevemark
Tel: (212) 433-4600
Email: scopus@reevemark.com

FAQ

What is the significance of the SITC presentation for Scopus BioPharma (SCPS)?

The presentation at the SITC showcases Scopus BioPharma's research advancements and potential impact in immunotherapy.

When is the Society for Immunotherapy of Cancer meeting taking place?

The SITC meeting is held from November 8-12, 2022, in Boston, Massachusetts.

What are the key assets of Duet BioTherapeutics?

Duet BioTherapeutics has three main CpG-STAT3 inhibitors: DUET-01 (RNA silencing), DUET-02 (Antisense), and DUET-03 (DNA-binding inhibitor).

What risks are associated with the forward-looking statements in the press release for SCPS?

The risks include uncertainties that could lead to actual results differing from expectations, as detailed in the company's SEC filings.